Conexeu Sciences appoints Miles Harrison as CEO

Conexeu Sciences Inc., a biotechnology company focused on regenerative medicine, announced the appointment of Miles D. Harrison as President and Chief Executive Officer. Harrison also joined the company's Board of Directors.

Harrison brings more than two decades of healthcare and aesthetics industry experience. He previously served as President and CEO of Galderma North America, managing products including Restylane, Sculptra, and Dysport. He co-founded and led Novaestiq Corp. from inception until its acquisition by Waldencast plc (NASDAQ: WALD) in four years. Harrison has served on the board of Castle Biosciences, Inc. (NASDAQ: CSTL) since 2020.

The Reno, Nevada-based company develops collagen-based regenerative medicine products through its CXU platform. Founded in late 2022, Conexeu emerged from over a decade of university research and holds patents across the United States, European Union, Japan, and Australia.

The company's lead product, Ten Minute Tissue, is a liquid dermal extracellular matrix that remains fluid at room temperature and forms a gel at body temperature. The product has undergone pilot clinical studies but remains investigational and has not received regulatory approval.

"Miles brings a rare combination of proven leadership, commercial discipline, market insight, and deep respect for science," said Jeff Sharpe, Chairman of Conexeu's Board of Directors.

Harrison stated the company aims to advance its collagen platform across wound care, dental, and aesthetics applications. Co-Founder and Chief Science Officer Dr. Claudia Chavez-Munoz said the platform provides a scaffold that mimics native tissue architecture.

The information is based on a company press release.

You May Also Be Interested In